2 Medtech Stocks Outperforming The S&P 500
Tuesday, Aug 18, 2026
The medical devices and equipment landscape is seeing a decisive rotation toward high-impact clinical utility and specialized care delivery. In an environment where hospital systems and outpatient providers demand clear diagnostic workflows and targeted surgical outcomes, capital is gravitating toward proven commercial solutions that solve critical clinical bottlenecks.
๐ One company is democratizing medical imaging by shrinking ultrasound technology onto a single semiconductor chip for accessible point-of-care diagnostics.
๐ The other provides specialized electrophysiology and surgical devices designed to treat complex atrial fibrillation, manage the left atrial appendage, and control postoperative pain.
๐ Both are capturing steady demand by addressing essential, non-elective clinical challenges across distinct stages of patient care.
We examine how Butterfly Network, Inc. (BFLY) and AtriCure, Inc. (ATRC) are carving out distinct operational niches across advanced healthcare equipment.
SpaceX. AI infrastructure. America's aging power grid.
Ross Givens believes the bigger opportunity could be where all three trends collide โ and he's identified 3 targeted investments positioned around that convergence.
His complete research is inside CONVERGENCE 2026.
See all 3 ideas with a $5 Live Action War Room trial >>
Our 1st Stock is
Butterfly Network, Inc. (NYSE: BFLY)
Butterfly Network, Inc. (NYSE: BFLY) is a digital health and medical device pioneer operating in the Health Care Equipment industry. The company has transformed medical imaging by developing Ultrasound-on-Chip technology, which replaces traditional piezoelectric crystals with semiconductor silicon to deliver accessible, handheld point-of-care ultrasound (POCUS) devices powered by proprietary cloud and AI software.
Business Model and Revenue Streams ๐ฆ
Butterfly Network generates revenue primarily through hardware sales of its whole-body handheld ultrasound devices, including the Butterfly iQ3, alongside recurring software subscriptions. Its SaaS platform provides medical institutions and individual clinicians with enterprise imaging workflows, cloud storage, diagnostic collaboration tools, and AI-guided clinical assistance.
The company is also expanding high-margin revenue streams via its Embedded business model, licensing and integrating its proprietary semiconductor ultrasound chips into third-party medical devices. Additionally, Butterfly is extending its reach beyond hospital networks into ambulatory care, home health, and global health settings.
Recent Performance and Corporate Developments ๐
Q2 2026 Financial Highlights: ๐ฐ
- Quarter ended June 30, 2026 revenue totaled $32.61 million, up 39.47% year-over-year.
- Quarterly net loss reported at $12.91 million, yielding an EPS of -$0.05.
- Trailing twelve-month price-to-sales ratio stands at approximately 17.44x against a market capitalization of $1.9 billion.
- Average trading volume remains highly liquid at approximately 10.87 million shares.
Strategic Initiatives and Mergers: ๐ค
Butterfly Network raised its 2026 financial outlook following accelerated momentum in its Embedded technology integrations and enterprise POCUS adoption. The company is advancing AI integration across its platform, bolstered by a partnership with Midjourney and adoption of its Compass AI tools, while laying operational groundwork for commercial revenue generation across Home and Community Care channels.
Profitability and Fair Value ๐ฏ
For the latest reported quarter ended June 30, 2026, Butterfly Network generated $32.61 million in revenue, representing 39.47% year-over-year growth, alongside a net loss of $12.91 million (an EPS of -$0.05). The company remains in an investment and scaling phase, driving operational leverage through accelerated enterprise POCUS adoption, Compass AI software subscriptions, and expanding embedded ultrasound partnerships.
Because the company remains unprofitable on a trailing twelve-month basis, traditional P/E and EV/EBITDA ratios are negative and omitted. Butterfly trades at a trailing price-to-sales multiple of roughly 17.4x to 21.4x, reflecting significant 1-year price action and market enthusiasm for its semiconductor-based platform. Sustaining this premium will hinge on executing margin expansion and delivering a clear pathway toward cash-flow breakeven.
Analyst Estimates and Ratings ๐
Analyst sentiment on Butterfly Network is positive, with a consensus profile of 2 Buy ratings, 0 Strong Buys, 0 Holds, and 0 Sells over the past six months. There have been no new buy-side rating upgrades over the trailing 90 days. Wall Street's favorable stance is driven by Butterfly's raised 2026 outlook and commercial traction across its embedded device portfolio.
Investor-Focused Takeaway: Is BFLY Right for Your Portfolio?
What to Watch in the Near Term: ๐
- Q3 2026 financial results scheduled for October 30, 2026, focusing on revenue trajectory and loss reduction.
- Commercial execution and initial revenue milestones from the Home and Community Care rollout targeted for Q4.
- Expansion and contract wins within the enterprise POCUS, Compass AI, and embedded ultrasound divisions.
- Executive presentation and commercial roadmap updates at the Annual J.P. Morgan Healthcare Conference on January 11, 2027.
Recommendation:
Butterfly Network offers strong technological differentiation in portable ultrasound and solid top-line momentum. However, following a massive 1-year advance, its premium price-to-sales valuation demands continued operational execution amid ongoing net losses. Investors should carefully balance its disruptive enterprise and AI opportunities against execution risks and the timeline required to achieve sustainable profitability.
Our 2nd Stock is
AtriCure, Inc. (NASDAQ: ATRC)
AtriCure, Inc. (NASDAQ: ATRC) is a leading medical device company focused on developing surgical solutions for atrial fibrillation (Afib), left atrial appendage (LAA) management, and postsurgical pain management. With a market capitalization of approximately $1.9 billion, AtriCure provides specialized electrophysiology and surgical technologies designed to improve patient outcomes in cardiothoracic surgery worldwide.
Business Model and Revenue Streams ๐ฆ
AtriCure generates revenue through the development, manufacture, and commercialization of proprietary medical devices across three primary therapeutic areas: surgical Afib ablation, LAA management, and cryoablation-based postsurgical pain relief. Its portfolio includes innovative radiofrequency ablation clamps, the AtriClip system, and cryoanalgesia devices.
The business model relies heavily on the recurring sale of single-use disposable tools, handpieces, and complementary capital equipment directly to hospitals and specialized surgical centers. Growth is driven by expanding clinical indications, increased adoption of concomitant surgical ablation, and rising demand for non-opioid postsurgical pain therapies.
Recent Performance and Corporate Developments ๐
Q2 2026 Financial Highlights: ๐ฐ
- Revenue reached $153.60 million for the quarter ended June 30, 2026, representing a 12.83% year-over-year increase.
- GAAP net income improved to $8.96 million for the quarter ended June 30, 2026.
- Diluted earnings per share (EPS) came in at $0.18 for the quarter ended June 30, 2026.
- Trailing twelve-month (TTM) price-to-sales ratio stands at approximately 3.32.
Strategic Initiatives and Mergers: ๐ค
AtriCure is executing on a strategic roadmap to achieve $1 billion in annual revenue, supported by the continued clinical rollout and market adoption of its EnCompass clamp system. The company is advancing key clinical trials in surgical Afib and expanding market penetration for its cryoablation postsurgical pain-management platform.
Profitability and Fair Value ๐ฏ
For the quarter ended June 30, 2026, AtriCure generated revenue of $153.60 million, up 12.83% year over year, and achieved positive net income of $8.96 million ($0.18 EPS). Growth continues to be supported by steady procedure volumes and uptake across its atrial fibrillation, left atrial appendage management, and postsurgical pain portfolios.
From a valuation perspective, ATRC trades at a TTM P/S of approximately 3.32x, alongside a high TTM P/E of 176.11x and TTM EV/EBITDA of 80.31x. These premium multiples reflect an early stage of GAAP profitability, meaning sustained operating leverage and execution toward larger revenue milestones will be critical to justify current price levels.
Analyst Estimates and Ratings ๐
Analyst consensus stands at 2 Buy ratings with zero Hold or Sell recommendations over the past six months. There have been no new buy-side upgrades onto Buy or Strong Buy during the trailing 90 days, with the latest street actions maintaining existing positive stances following solid Q2 financial performance.
Investor-Focused Takeaway: Is ATRC Right for Your Portfolio?
What to Watch in the Near Term: ๐
- Q3 2026 earnings release scheduled for October 29, 2026, tracking revenue trajectory and sustained net profitability.
- AFib clinical data updates and EnCompass platform adoption figures expected on November 8, 2026.
- Commercial execution and margin progress toward management's long-term $1 billion revenue ambition.
- Impact of recent insider share sales on overall institutional ownership stability.
Recommendation:
AtriCure offers an attractive medtech growth narrative supported by double-digit revenue expansion and a turn to quarterly profitability. Nonetheless, elevated trailing valuation multiples demand flawless execution in clinical adoption and cost discipline. ATRC remains a balanced watch for growth-oriented investors monitoring specialized health care equipment.
BIGGER THAN SPACEX? ๐
Elon Musk is preparing to roll out what he calls "the biggest product ever of any kind."
James Altucher calls it "A.R.M."
Elon says the opportunity could eventually drive $25 trillion in new wealth โ and James believes he's uncovered the little-known company supplying the critical technology behind it.
See how to get positioned before "A.R.M." takes off >>
Final Take: Portable Imaging Innovation Meets Cardiothoracic Precision
Modern medical device evolution is moving along two critical tracks: decentralizing complex diagnostics to the bedside and engineering specialized, high-barrier tools for the operating room. Advancing patient outcomes requires both accessible frontline detection and refined surgical intervention.
That dynamic defines the distinct commercial opportunities behind Butterfly Network (BFLY) and AtriCure (ATRC).
๐ฉบ Butterfly Network (BFLY) โ Democratizing Medical Imaging via Silicon
โ Proprietary Ultrasound-on-Chip semiconductor design that replaces traditional piezoelectric crystals with accessible handheld hardware
โ Dual-stream business model blending device sales (such as the Butterfly iQ3) with high-margin recurring SaaS subscriptions for AI guidance and enterprise imaging workflows
โ Large addressable runway as point-of-care ultrasound expands across hospital networks, ambulatory clinics, and global health systems
โค Best for: Speculative growth investors seeking long-term upside in digital health disruption, diagnostic software monetization, and point-of-care medical hardware adoption.
๐ซ AtriCure (ATRC) โ High-Precision Surgical Solutions for Cardiothoracic Care
โ Established market position in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management via its proprietary AtriClip platform
โ Diversified clinical revenue spanning radiofrequency ablation, stroke risk reduction, and cryoanalgesia devices for non-opioid postsurgical pain management
โ Deep operating-room entrenchment with a strong global footprint across specialized cardiothoracic and electrophysiology surgical suites
โค Best for: Investors seeking established medtech exposure driven by specialized surgical moats, expanding electrophysiology procedures, and proven hospital demand.
Investor Insight
๐ฑ Looking for high-upside digital health disruption tied to silicon-based imaging and AI diagnostic subscriptions? โ BFLY
๐ฅ Looking for established surgical devices with strong clinical moats in cardiothoracic and Afib care? โ ATRC
Bottom Line:
The medical technology landscape rewards companies that either fundamentally lower the barrier to essential diagnostics or solve intricate, high-stakes surgical challenges. Butterfly Network is modernizing imaging by turning whole-body ultrasound into a pocket-sized, cloud-connected tool, while AtriCure provides the essential hardware surgeons rely on for complex cardiac interventions. Both deliver targeted exposure to healthcare innovation across distinct stages of patient care.
Research and education only. Not investment advice. Do your own research.
โ